[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Hemophilia |
|
|
Clinical Trial: Epidemiology and Immunology of Hemophilia A Inhibitors
This study has been completed.
Purpose
To determine the risk factors associated with inhibitor formation in hemophilia A and to study the mechanism of tolerance in the murine hemophilia A model.
| Condition |
|---|
| Blood Disease Hemophilia A |
MedlinePlus related topics: Blood and Blood Disorders; Hemophilia
Study Type: Observational
Study Design: Natural History
Study start: June 1998; Study completion: August 2003
BACKGROUND: The major hypothesis of this study is that suppression of immunoregulatory cytokines will prevent factor VIII inhibitor formation in the hemophilia A murine model: if successful, a treatment protocol could be developed for individuals identified to be at highest risk for inhibitor formation. Through this approach to the epidemiology and immunology of inhibitor formation, the health care of individuals with hemophilia may be improved.
The study is in response to a Request for Applications released in 1998 on the Immunogenetics of Inhibitor Formation in Hemophilia. .
DESIGN NARRATIVE: A case-control study is conducted comparing prevalent hemophilia patients with inhibitors identified in the HMS Study with three age-matched controls without inhibitors to determine clinical and laboratory characteristics associated with inhibitor development. A histocompatibility study is conducted identifying patterns of HLA Class II antigens by molecular typing in hemophilic subjects identified in HMS, with and without inhibitors, which may be linked to inhibitor formation. An animal tolerance study is conducted in the hemophilia A murine model, evaluating blockade of T cell costimulatory pathways by CTLA4-Ig and anti-CD40L mAb, to prevent inhibitor formation.
Eligibility
Genders Eligible for Study: Male
Criteria
Location Information
M.V. Ragni, University of Pittsburgh
More Information
Record last reviewed: August 2004
Last Updated: October 13, 2004
Record first received: May 25, 2000
ClinicalTrials.gov Identifier: NCT00005518
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Bleeding Disorders (National Women's Health Information Center)
- Bleeding Disorders: Financial and Insurance Issues (National Hemophilia Foundation)

Not Signed In -


